Literature DB >> 15100125

Small (<or= 2 cm) hepatic lesions in colorectal cancer patients: detection and characterization on mangafodipir trisodium-enhanced MRI.

Kyoung Won Kim1, Ah Young Kim, Tae Kyoung Kim, Seong Ho Park, Hyun Jin Kim, Young Kyung Lee, Mi-Suk Park, Hyun Kwon Ha, Pyo Nyun Kim, Jin Cheon Kim, Moon-Gyu Lee.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate whether mangafodipir trisodium (MnDPDP)-enhanced MRI improves the detection and characterization of small (<or= 2 cm) hepatic lesions in patients with colorectal carcinoma, compared with helical CT. SUBJECTS AND METHODS. Sixty-nine patients who had or were suspected of having focal liver lesions underwent helical CT and MnDPDP-enhanced MRI and constituted the study population. Two experienced radiologists independently reviewed CT and MR images for the number of hepatic lesions seen and whether the lesion appeared to be benign or metastatic; their interpretations were correlated with the reference diagnoses, including histopathologic diagnoses in 35 patients. The lesions were categorized as small (<or= 2.0 cm in diameter) or large (> 2.0 cm). The differences between MnDPDP-enhanced MRI and helical CT with regard to the detection rates for hepatic lesions and metastases and with regard to the false-positive rates for hepatic metastases were analyzed using the McNemar test. The performances of MnDPDP-enhanced MRI and helical CT in indicating metastases of focal liver lesions were analyzed using receiver operating characteristic curves.
RESULTS: No statistically significant differences were seen between MnDPDP-enhanced MRI and helical CT in the detection of all hepatic lesions (p = 0.383) and small lesions (p = 0.210). However, concerning the differentiation between benign and metastatic lesions, MnDPDP-enhanced MRI was superior to helical CT both for all hepatic lesions (p = 0.023) and for small lesions (p = 0.015), and remained better when the analyses were restricted to patients with histopathologic confirmation (p = 0.023 for both). MnDPDP-enhanced MRI changed the diagnosis of hepatic metastasis in nine (13.0%) of 69 patients. Of 12 metastases that were found on MnDPDP-enhanced MRI and missed on helical CT, 11 lesions (91.7%) were small. MnDPDP-enhanced MRI showed a significantly greater detection rate than helical CT for small hepatic metastases (p = 0.022). MnDPDP-enhanced MRI was better when the analyses were restricted to patients with histopathologic confirmation (p = 0.043).
CONCLUSION: Although MnDPDP-enhanced MRI is equal to helical CT in detection of both all hepatic lesions and small lesions in patients with colorectal carcinoma, it is superior to CT in characterization of the lesions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15100125     DOI: 10.2214/ajr.182.5.1821233

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  11 in total

1.  Combining diffusion-weighted MRI with Gd-EOB-DTPA-enhanced MRI improves the detection of colorectal liver metastases.

Authors:  D-M Koh; D J Collins; T Wallace; I Chau; A M Riddell
Journal:  Br J Radiol       Date:  2011-12-13       Impact factor: 3.039

2.  Contrast-enhanced intraoperative ultrasound improves detection of liver metastases during surgery for primary colorectal cancer.

Authors:  Ankur J Shah; Mark Callaway; Michael G Thomas; Meg D Finch-Jones
Journal:  HPB (Oxford)       Date:  2010-04       Impact factor: 3.647

Review 3.  [Radiological diagnosis of hepatic tumors. Part II: Identification and differential diagnosis].

Authors:  G Layer; S Delorme
Journal:  Radiologe       Date:  2007-10       Impact factor: 0.635

4.  Comparison of contrast-enhanced ultrasonography versus baseline ultrasound and contrast-enhanced computed tomography in metastatic disease of the liver: diagnostic performance and confidence.

Authors:  Emilio Quaia; Mirko D'Onofrio; Alessandro Palumbo; Stefania Rossi; Stefano Bruni; Maria Cova
Journal:  Eur Radiol       Date:  2006-03-22       Impact factor: 5.315

5.  Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist(®))-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre.

Authors:  V O Chan; J P Das; J F Gerstenmaier; J Geoghegan; R G Gibney; C D Collins; S J Skehan; D E Malone
Journal:  Ir J Med Sci       Date:  2012-03-17       Impact factor: 1.568

6.  Diagnostic efficacy of gadoxetic acid-enhanced MRI for the detection and characterisation of liver metastases: comparison with multidetector-row CT.

Authors:  Y K Kim; G Park; C S Kim; H C Yu; Y M Han
Journal:  Br J Radiol       Date:  2012-05       Impact factor: 3.039

7.  Detection and characterization of liver metastases: 16-slice multidetector computed tomography versus superparamagnetic iron oxide-enhanced magnetic resonance imaging.

Authors:  Young Kon Kim; Seog Wan Ko; Seung Bae Hwang; Chong Soo Kim; Hee Chul Yu
Journal:  Eur Radiol       Date:  2006-02-02       Impact factor: 5.315

8.  Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination.

Authors:  D M Koh; G Brown; A M Riddell; E Scurr; D J Collins; S D Allen; I Chau; D Cunningham; N M deSouza; M O Leach; J E Husband
Journal:  Eur Radiol       Date:  2008-01-12       Impact factor: 5.315

9.  Metachronous liver metastases and resectability: Fong's score and laparoscopic evaluation.

Authors:  G Li Destri; F Di Benedetto; B Torrisi; T R Portale; F Mosca; R Vecchio; A Di Cataldo; S Puleo
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

10.  Appearances of colorectal hepatic metastases at diffusion-weighted MRI compared with histopathology: initial observations.

Authors:  E D Scurr; D J Collins; L Temple; N Karanjia; M O Leach; D-M Koh
Journal:  Br J Radiol       Date:  2011-01-11       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.